ACADIA Pharma

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ACADIA Pharma reports strong Q4 earnings, eyes trofinetide launch

ACADIA Pharma showcased strong financial performance and strategic advancements in Q4 2022, with a focus on NUPLAZID and trofinetide for Rett syndrome treatment.
The company's commitment to innovation, positive payer discussions, and promising study results position it well for future success in the neuroscience space.
While facing challenges in managing expenses and post-approval logistics, ACADIA has opportunities to drive growth through market acceptance of trofinetide and expanding its patient base.
Overall, ACADIA's performance, strengths, and strategic outlook indicate a promising trajectory for the company, with key milestones ahead in 2023.

ACADIA Pharma reports solid Q1 performance and navigates strategic decisions

ACADIA Pharma's Q1 2023 performance reflects strong market acceptance of DAYBUE and steady growth in NUPLAZID market share.
The company's financial stability, progress in clinical programs, and strategic focus on real-world evidence studies position it well for future growth.
Challenges in decision-making, seasonality, and balancing profitability with pipeline expansion require strategic navigation.
Opportunities lie in exploring broader patient populations, leveraging real-world evidence, and making strategic decisions on the priority review voucher.

ACADIA Pharma reports robust Q2 sales, eyes global expansion

ACADIA Pharma's Q2 earnings call highlighted strong sales performance and milestone of cash flow neutrality
NUPLAZID and DAYBUE driving revenue growth, with plans for global expansion and new product approvals
Challenges include market dynamics in Parkinson's disease and addressing unmet needs in CNS disorders
Opportunities lie in late-stage programs, expanding market presence, and enhancing patient support initiatives

ACADIA Pharma reports robust Q3 earnings, eyes global expansion

ACADIA Pharma's Q3 2023 showcased strong financial performance, robust pipeline programs, and positive market reception for DAYBUE and NUPLAZID
Challenges with insurance coverage and study timelines were noted, but opportunities in global expansion and real-world evidence support growth potential
Overall, ACADIA Pharma's earnings call highlighted a solid foundation for continued growth and market leadership in neurological and psychiatric treatments

ACADIA Pharma posts record revenues, guides strong growth for 2024

ACADIA Pharma's Q4 earnings call highlighted strong commercial performance, robust pipeline, and solid financial position.
The company's focus on persistency rates, compliance, and guidance scenarios underpin their growth strategy for 2024.
Challenges include pipeline uncertainties and operational complexities, while opportunities lie in market expansion and optimization strategies.
Overall, ACADIA Pharma's emphasis on execution and strategic planning positions them for continued success in the pharmaceutical market.

ACADIA Pharma reports robust Q1 earnings, eyes global expansion

ACADIA Pharma's Q1 2024 showcased strong revenue growth and promising sales performance for key products.
The company's robust pipeline and focus on global expansion offer avenues for sustained growth.
Challenges in gross to net tracking and cost optimization require attention for future profitability.

ACADIA Pharma reports robust Q2 earnings, eyes market expansion opportunities

ACADIA Pharma's strong Q2 performance, driven by NUPLAZID and DAYBUE, showcases revenue growth and strategic marketing initiatives.
The company's financial stability, successful patient engagement strategies, and upcoming awareness campaigns position it well for future growth.
While facing challenges in sustaining sales momentum and market competition, ACADIA Pharma has opportunities to expand market reach and enhance therapy understanding.

ACADIA Pharma reports robust Q3 earnings and outlines growth strategies

ACADIA Pharma's Q3 earnings reflect strong sales performance, a robust financial position, and a focus on advancing its pipeline assets for future growth.
The company's new CEO brings industry expertise and a vision for expansion, while challenges in market expansion and competition require strategic planning.
Opportunities for ACADIA Pharma lie in international expansion, pipeline development, and continued efforts to drive growth through effective commercial strategies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Fate Therapeutics

Pieris Pharma

Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so.

3 Biotech Stocks to Watch Now

Clovis Oncology

Acadia Pharmaceuticals and Clovis Oncology may be turnaround stories in the making.

Can These Former Biotech Growth Stocks Regain Their Form?

Acadia was blindsided by NUPLAZID's CRL for treating hallucinations and delusions linked with dementia-related psychosis “DRP”. The loss of all expected near-term DRP sales chopped the share price in half. COVID-19 has hurt in-person patient office visits, which has hindered commercial growth. However, the company was able to find some encouraging trends in their Q2 earnings results.

Acadia Pharmaceuticals: Refunding A Former Champion

Acadia Healthcare

Acadia Healthcare (ACHC) continues to gain from top-line growth, solid demand for behavioral health services, several growth-related initiatives and reducing debt levels.

Here's Why You Should Buy Acadia Healthcare (ACHC) Stock Now

We believe that Acadia Pharmaceuticals stock, a biopharmaceutical company focused on neuroscience drugs, is a good buying opportunity at the present time. ACAD stock trades around $17 levels currently and it is, in fact, down 64% from its pre-Covid high of around $47 in February 2020.

How Does Acadia Stock Performance In The Current Crisis Compare With That In 2008?

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?

Acadia (ACAD) Down 10.8% Since Last Earnings Report: Can It Rebound?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Elena Ridloff, Executive Vice President and Chief Financial Officer (CFO), will be leaving the company effective September 10, 2021 to join another biopharmaceutical company. Mark Schneyer, Senior Vice President, Business Development and Chief Business Officer, will serve as Acadia's interim Chief Financial Officer. The company is conducting a formal search for a new CFO. “On behalf of all of us at Acadi

Acadia Pharmaceuticals Announces Executive Leadership Change

AbCellera Biologics

Amicus Therapeutics

Sarepta Therapeutics

TG Therapeutics

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia's presentation will be accessible on the company's website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through September 12, 2021. About Acadia Pharm

Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021.

ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

Booking Hlds

Incyte

Earnings season is winding down. With that come analyst projections for where these stocks and the market in general could go in the coming months.

4 Bullish Stock Picks After Earnings With Huge Potential Upside

ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q2 2021 Results - Earnings Call Transcript

Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021. “NUPLAZID performed well in the second quarter of 2021, highlighted by our ability to drive growth while still navigating the continued impact from the pandemic,” said Steve Davis, Chief Executive Officer. “We recently completed a Type A meeting with the FDA regarding pimavanserin for dementia-related psychosis and plan to continue our engagem

Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that the New England Journal of Medicine published results from the Phase 3 HARMONY study, an international, double-blind, placebo-controlled relapse prevention trial in 392 patients evaluating pimavanserin as an investigational treatment in patients with hallucinations and delusions associated with dementia-related psychosis (DRP). The study included patients across five subgroups of dementia: Alzheimer's di

The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia's management team will also host a conference call and webcast on August 4, 2021, at 4:30 p.m. Eastern Time to discuss financial results and operations. The conference call may be accessed by dialing 855-638-4820 for participants in the United States or Canada and 443-8

Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that three scientific presentations in dementia-related psychosis (DRP) will be shared at the Alzheimer's Association International Conference® 2021 (AAIC®), being held July 26-30, 2021 in Denver, Colo., and virtually. The poster presentations include two analyses of patients who have neurodegenerative disease taking pimavanserin while also receiving other antidementia medication. One presentation focuses on

Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer's Association International Conference 2021 (AAIC)

New York, New York--(Newsfile Corp. - June 21, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 21, 2021 - ACAD

Los Angeles, California--(Newsfile Corp. - June 21, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...

DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

San Francisco, California--(Newsfile Corp. - June 19, 2021) - Hagens Berman urges Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) investors with significant losses to submit your losses now.Class Period: June 15, 2020 - Apr. 4, 2021Lead Plaintiff Deadline: June 21, 2021Visit: www.hbsslaw.com/investor-fraud/ACADContact An Attorney Now: ACAD@hbsslaw.com844-916-0895Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) Securities Fraud Action:The complaint alleges that Defendants misrepresented facts concerning Acadia's supplemental new drug application

ACAD INVESTOR DEADLINE MONDAY: Hagens Berman Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact the Firm Now

New York, New York--(Newsfile Corp. - June 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Southern District of New York. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD

Los Angeles, California--(Newsfile Corp. - June 18, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ACADIA Pharmaceuticals Inc. ("Acadia" or "the Company") (NASDAQ: ACAD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 15, 2020 and April 4, 2021, inclusive...

DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - June 18, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ: ACAD) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired ACADIA securities between June 15, 2020 and April 4, 2021, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting...

Final Deadline for Investors to Actively Participate in ACADIA Pharmaceuticals Inc. (ACAD) Class Action: Bronstein, Gewirtz & Grossman, LLC

New York, New York--(Newsfile Corp. - June 17, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Acadia Pharmaceuticals Inc. ("Acadia") (NASDAQ: ACAD) between June 15, 2020 and April 4, 2021.If you suffered a loss, contact us at the link below. There is no cost or obligation to you.http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16974&wire=5

ACAD LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Acadia Pharmaceuticals Inc.

New York, New York--(Newsfile Corp. - June 17, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) alleging that the Company violated federal securities laws.Class Period: June 15, 2020 and April 4, 2021Lead Plaintiff Deadline: June 18, 2021Learn more about your recoverable losses in ACAD:

ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders

News for ACADIA Pharma Stock (ACAD)